➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Colorcon
Mallinckrodt
Express Scripts
Baxter

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 9,616,121

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,616,121
Title:Therapeutic combinations for treating Johne\'s disease
Abstract: In alternative embodiments, the invention provides a \"triple combination\" therapy for treating, ameliorating and preventing Crohn\'s Disease (or Crohn syndrome, terminal or distal ileitis or regional enteritis) or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne\'s disease, including genetically-predisposed and chronic disorders, where the microbial or bacterial flora of the bowel is at least one causative or symptom-producing factor; and compositions for practicing same. In alternative embodiments, methods and compositions of the invention comprise or comprise use of therapies, medications, formulations and pharmaceuticals comprising active agents that can suppress or eradicate the microbiota super-infection that causes Crohn\'s Disease or paratuberculosis infection in mammals. In alternative embodiments, the methods and uses of the invention for treating, ameliorating and preventing Crohn\'s Disease and complications of Crohn\'s Disease, or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne\'s disease, comprises administration to an individual (human or mammal) in need thereof: (1) an anti-TNF.alpha. composition, or a composition capable of down-modulating TNF.alpha. activity; (2) a Hyperbaric Oxygen Treatment, or HBOT; and (3) an anti-Mycobacterium avium sub species paratuberculosis (MAP) (an anti-MAP) agent, composition or therapy.
Inventor(s): Agrawal; Gaurav (Manly, AU)
Assignee: Center for Digestive Diseases (New South Wales, AU)
Application Number:14/405,384
Patent Claims:see list of patent claims

Details for Patent 9,616,121

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 001 1998-05-12   Start Trial Center for Digestive Diseases (New South Wales, AU) 2032-06-04 RX search
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 002 1998-05-12   Start Trial Center for Digestive Diseases (New South Wales, AU) 2032-06-04 RX search
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial Center for Digestive Diseases (New South Wales, AU) 2032-06-04 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Dow
Express Scripts
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.